Terms: = Pancreatic cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
631 results:
1. [A Case of Advanced Gastric cancer Treated with Conversion Surgery followed by Nivolumab Combination Chemotherapy].
Sekino N; Natsume T; Tanaka H; Kainuma O; Sato Y; Note H; Yoshioka T; Kamata T; Odera H; Uchiyama M; Maruyama T; Takahashi H; Hirano S
Gan To Kagaku Ryoho; 2024 Apr; 51(4):417-420. PubMed ID: 38644309
[TBL] [Abstract] [Full Text] [Related]
2. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
[TBL] [Abstract] [Full Text] [Related]
3. [The use of targeted therapies in gastrointestinal oncology].
Lange S
Dtsch Med Wochenschr; 2024 Apr; 149(8):440-446. PubMed ID: 38565117
[TBL] [Abstract] [Full Text] [Related]
4. Combined KRAS-MAPK pathway inhibitors and her2-directed drug conjugate is efficacious in pancreatic cancer.
Bulle A; Liu P; Seehra K; Bansod S; Chen Y; Zahra K; Somani V; Khawar IA; Chen HP; Dodhiawala PB; Li L; Geng Y; Mo CK; Mahsl J; Ding L; Govindan R; Davies S; Mudd J; Hawkins WG; Fields RC; DeNardo DG; Knoerzer D; Held JM; Grierson PM; Wang-Gillam A; Ruzinova MB; Lim KH
Nat Commun; 2024 Mar; 15(1):2503. PubMed ID: 38509064
[TBL] [Abstract] [Full Text] [Related]
5. Tyr352 as a Predominant Phosphosite in the Understudied Kinase and Molecular Target, HIPK1: Implications for cancer Therapy.
Sanjeev D; George M; John L; Gopalakrishnan AP; Priyanka P; Mendon S; Yandigeri T; Nisar M; Nisar M; Kanekar S; Balaya RDA; Raju R
OMICS; 2024 Mar; 28(3):111-124. PubMed ID: 38498023
[TBL] [Abstract] [Full Text] [Related]
6. A case report of carcinoma of the papilla of Vater associated with a hyperplasia-dysplasia-carcinoma sequence by pancreaticobiliary maljunction.
Korai T; Kimura Y; Watanabe K; Low SK; Imamura M; Nagayama M; Kukita K; Murakami T; Kato T; Kondo Y; Kyuno D; Sugawara T; Murota A; Kawakami Y; Masaki Y; Nakase H; Takemasa I
World J Surg Oncol; 2024 Feb; 22(1):63. PubMed ID: 38389074
[TBL] [Abstract] [Full Text] [Related]
7. Anti-collagenase, Anti-elastase, Anti-urease, and Anti-cancer Potentials of Isokaempferide as Natural Compound: In vitro and in silico Study.
Yin Q; Zhang H; Huang T; Liu B; Negm S; El-Kott AF
J Oleo Sci; 2024; 73(2):187-199. PubMed ID: 38311409
[TBL] [Abstract] [Full Text] [Related]
8. Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised controlled trial of individuals with type 2 diabetes.
Bull CJ; Hazelwood E; Legge DN; Corbin LJ; Richardson TG; Lee M; Yarmolinsky J; Smith-Byrne K; Hughes DA; Johansson M; Peters U; Berndt SI; Brenner H; Burnett-Hartman A; Cheng I; Kweon SS; Le Marchand L; Li L; Newcomb PA; Pearlman R; McConnachie A; Welsh P; Taylor R; Lean MEJ; Sattar N; Murphy N; Gunter MJ; Timpson NJ; Vincent EE
EBioMedicine; 2024 Feb; 100():104977. PubMed ID: 38290287
[TBL] [Abstract] [Full Text] [Related]
9. MNX1 Promotes Anti-her2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in her2-Positive Breast cancer.
Chi W; Xiu B; Xiong M; Wang X; Li P; Zhang Q; Hou J; Sang Y; Zhou X; Chen M; Zheng S; Zhang L; Xue J; Chi Y; Wu J
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203393
[TBL] [Abstract] [Full Text] [Related]
10. Immunohistochemical FAP Expression Reflects
Spektor AM; Gutjahr E; Lang M; Glatting FM; Hackert T; Pausch T; Tjaden C; Schreckenberger M; Haberkorn U; Röhrich M
J Nucl Med; 2024 Jan; 65(1):52-58. PubMed ID: 38167622
[TBL] [Abstract] [Full Text] [Related]
11. Prioritization of Fluorescence In Situ Hybridization (FISH) Probes for Differentiating Primary Sites of neuroendocrine Tumors with Machine Learning.
Pietan L; Vaughn H; Howe JR; Bellizzi AM; Smith BJ; Darbro B; Braun T; Casavant T
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139230
[TBL] [Abstract] [Full Text] [Related]
12. The genomic and immune landscapes of gastric cancer and their correlations with her2 amplification and PD-L1 expression.
Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
[TBL] [Abstract] [Full Text] [Related]
13. Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis.
Yang H; Li S; Li W; Yang Y; Zhang Y; Zhang S; Hao Y; Cao W; Xu F; Wang H; Du G; Wang J
Carcinogenesis; 2024 Apr; 45(4):262-273. PubMed ID: 37997385
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With her2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
[TBL] [Abstract] [Full Text] [Related]
15. Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer.
Han J; Xu J; Liu Y; Liang S; LaBella KA; Chakravarti D; Spring DJ; Xia Y; DePinho RA
Genes Dev; 2023 Sep; 37(17-18):818-828. PubMed ID: 37775182
[TBL] [Abstract] [Full Text] [Related]
16. Analysis of clinicopathological characteristics and prognostic factors of early-stage human epidermal growth factor receptor 2 (her2)-low breast cancer: Compared with her2-0 breast cancer.
Wu Q; Yang F; Liu Y; Zhang H; Zhang S; Xin L; Xu L
Cancer Med; 2023 Oct; 12(19):19560-19575. PubMed ID: 37772432
[TBL] [Abstract] [Full Text] [Related]
17. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract cancer (SGNTUC-019): A Phase II Basket Study.
Nakamura Y; Mizuno N; Sunakawa Y; Canon JL; Galsky MD; Hamilton E; Hayashi H; Jerusalem G; Kim ST; Lee KW; Kankeu Fonkoua LA; Monk BJ; Nguyen D; Oh DY; Okines A; O'Malley DM; Pohlmann P; Reck M; Shin SJ; Sudo K; Takahashi S; Van Marcke C; Yu EY; Groisberg R; Ramos J; Tan S; Stinchcombe TE; Bekaii-Saab T
J Clin Oncol; 2023 Dec; 41(36):5569-5578. PubMed ID: 37751561
[TBL] [Abstract] [Full Text] [Related]
18. Clinically conserved genomic subtypes of gastric adenocarcinoma.
Jeong YS; Eun YG; Lee SH; Kang SH; Yim SY; Kim EH; Noh JK; Sohn BH; Woo SR; Kong M; Nam DH; Jang HJ; Lee HS; Song S; Oh SC; Lee J; Ajani JA; Lee JS
Mol Cancer; 2023 Sep; 22(1):147. PubMed ID: 37674200
[TBL] [Abstract] [Full Text] [Related]
19. ERCC6L facilitates the onset of mammary neoplasia and promotes the high malignance of breast cancer by accelerating the cell cycle.
Yang H; Zhen X; Yang Y; Zhang Y; Zhang S; Hao Y; Du G; Wang H; Zhang B; Li W; Wang J
J Exp Clin Cancer Res; 2023 Sep; 42(1):227. PubMed ID: 37667329
[TBL] [Abstract] [Full Text] [Related]
20. The Mutation Portraits of Oncogenes and Tumor Supressor Genes in Predicting the Overall Survival in pancreatic cancer: A Bayesian Network Meta-Analysis.
Aryanti C; Uwuratuw JA; Labeda I; Raharjo W; Lusikooy RE; Rauf MA; Mappincara A; Sampetoding S; Kusuma MI; Syarifuddin E
Asian Pac J Cancer Prev; 2023 Aug; 24(8):2895-2902. PubMed ID: 37642079
[TBL] [Abstract] [Full Text] [Related]
[Next]
